『MENA MedTech Insights』のカバーアート

MENA MedTech Insights

MENA MedTech Insights

著者： Ran Chen
無料で聴く

このコンテンツについて

 Welcome to MENA MedTech Insights, the definitive podcast for professionals in the Middle East and North Africa's rapidly growing medical technology sector. Each episode, we explore the latest innovations, market trends, and regulatory landscapes, featuring exclusive interviews with the founders, investors, and leaders who are shaping the future of healthcare in the region.Copyright 2025 Ran Chen 生物科学 科学 経済学
エピソード
  • Pure Global's MENA MedTech Playbook: Navigating Saudi Arabia & UAE Regulations with Your EU EUDAMED Strategy.

    Pure Global's MENA MedTech Playbook: Navigating Saudi Arabia & UAE Regulations with Your EU EUDAMED Strategy.
    2025/10/17
    This episode of MENA MedTech Insights dives into the critical regulatory nuances for medical device companies expanding into the MENA region, particularly those with existing EU supply chains and approvals. We uncover why a CE mark is only the beginning of the journey and explore the growing divergence between EU standards, like EUDAMED, and the specific requirements of key markets like Saudi Arabia and the UAE. We break down the common assumption that EU compliance guarantees smooth entry into the Gulf. Learn how local data requirements, mandatory labeling laws, and the crucial choice of an in-country representative can make or break your market access strategy. This is essential listening for any regulatory affairs professional or business leader looking to capture the immense opportunity in the region without falling into common regulatory traps. A European MedTech firm secured a major distribution deal for their innovative cardiovascular stent in the Gulf, contingent on a 6-month launch timeline. They submitted their CE-marked technical file to the Saudi authorities, assuming a quick approval. However, their launch was halted for over a year because their EUDAMED-formatted UDI data was incompatible with the Saudi UDI system, and their chosen distributor lacked the regulatory expertise to resolve the issue, jeopardizing the entire commercial partnership. Key Takeaways: • Is your CE mark still a golden ticket for market access in Saudi Arabia and the UAE? • How can you leverage your EUDAMED preparation for faster entry into MENA markets instead of seeing it rejected? • What are the hidden risks of appointing a commercial distributor as your sole legal representative? • Are your labeling and technical documents truly compliant with local Arabization and data requirements? • How is the rise of national UDI databases in the Gulf impacting your global supply chain? • What steps should you take today to future-proof your regulatory strategy for the entire MENA region? At Pure Global, we specialize in turning these complex regulatory challenges into streamlined market access. Our integrated approach allows you to use a single, efficient process to enter multiple global markets, including the EU and key MENA countries. With local experts on the ground in over 30 markets, we manage everything from regulatory strategy and dossier submission to acting as your independent legal representative. Don’t let regulatory hurdles slow your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn how we can accelerate your global expansion.
    続きを読む 一部表示
    2 分
  • MENA MedTech Strategy: Why Saudi Arabia & UAE Demand Regulatory Clarity Before Budgeting | A Pure Global Insight

    MENA MedTech Strategy: Why Saudi Arabia & UAE Demand Regulatory Clarity Before Budgeting | A Pure Global Insight
    2025/10/16
    In this episode of MENA MedTech Insights, we explore the number one reason why medical device companies fail when entering markets like Saudi Arabia and the UAE: a lack of upfront regulatory clarity. We break down why a detailed understanding of the authorities, device classifications, and submission mechanics is non-negotiable *before* a single dollar of the budget is spent. Discover the common pitfalls that lead to massive budget overruns and months of delays. We use the real-world example of a company with a CE-marked device that plans for a simple registration in Saudi Arabia, only to be blindsided by the complex requirements of appointing a local Authorized Representative and navigating the SFDA's specific GHAD submission portal, costing them dearly in both time and money. Key Takeaways: * What is the single biggest mistake companies make before budgeting for MENA market entry? * Why is knowing the specific submission portal, like Saudi's GHAD system, critical *before* you start? * How can prerequisite requirements in the UAE, such as manufacturer registration, completely halt your market access plan? * Are you accounting for the hidden costs and timelines of appointing a local in-country representative? * Why is your CE mark or FDA approval just a starting point, not a free pass, in the MENA region? * How can a consolidated "regulatory intelligence report" de-risk your entire market entry strategy? * What specific questions should you ask to ensure your budget is realistic and defensible? At Pure Global, we provide this critical upfront clarity. Our end-to-end regulatory consulting, powered by local expertise and advanced AI tools, helps you build a predictable and successful market access strategy for the MENA region and beyond. Don't gamble with your global expansion. Contact us for a strategic consultation at info@pureglobal.com or visit https://pureglobal.com/.
    続きを読む 一部表示
    2 分
  • Unlocking MENA MedTech Markets: How Pure Global Turns Your Saudi Arabia SFDA Submission into a Cross-Region Scaling Blueprint

    Unlocking MENA MedTech Markets: How Pure Global Turns Your Saudi Arabia SFDA Submission into a Cross-Region Scaling Blueprint
    2025/10/15
    Expanding your MedTech footprint in the MENA region is far more complex than a single market entry. Each country, from Saudi Arabia to the UAE, presents unique regulatory and commercial hurdles. This episode of MENA MedTech Insights dives into a powerful strategy: using your initial regulatory submission as the blueprint for rapid, compliant, and successful cross-regional scaling. We explore the critical details of this approach through a common scenario. Imagine a company gains market approval in Saudi Arabia but then faces major setbacks when its marketing materials are flagged for non-compliance by the SFDA. The claims made, while standard in other regions, contradict the specific data approved in their regulatory dossier. This disconnect between the regulatory and commercial teams leads to costly revisions, delays, and reputational damage. This episode explains how to avoid this pitfall by integrating your regulatory and market access efforts from day one. Key Takeaways: • Why is treating the diverse MENA region as a single market a fundamental strategic error? • How can the technical details in your Saudi SFDA submission file become your most powerful tool for expansion into the UAE and Egypt? • What are the critical SFDA labeling and Instructions for Use (IFU) requirements that many foreign companies get wrong? • How does a unified regulatory and commercialization team prevent costly post-launch compliance penalties? • What is the “submission-led scaling” strategy and how does it significantly reduce your time-to-market? • Why do training materials for clinicians in Riyadh require a different approach than those for clinicians in Dubai? • How can you leverage a single regulatory process to gain access to multiple MENA markets simultaneously? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies. We combine local expertise with advanced AI and data tools to streamline global market access and turn your regulatory success into commercial domination. To learn how we can build your MENA expansion strategy, contact us at info@pureglobal.com or visit https://pureglobal.com/.
    続きを読む 一部表示
    2 分
まだレビューはありません